Latest Financial Updates

Read latest financial news update from our blog

EPFO declares 8.15 pc as rate of interest on employees' provident fund for 2022-23
EPFO declares 8.15 pc as rate of interest on employees' provident fund for 2022-23

Retirement fund body EPFO fixed 8.15 per cent rate of interest on employees' provident fun...

Admin | Finance | 3 months ago

The meta-view from meta-nowhere
The meta-view from meta-nowhere

Pseudo-objectivity about pseudo-objectivity Jay Rosen coined the phrase “the view from no...

Admin | Finance | 3 months ago

SVB, resolved
SVB, resolved

This article is an on-site version of our Unhedged newsletter. Sign up here to get the new...

Admin | Finance | 3 months ago

Eye on Lithium: Is Albemarle’s bid for LTR the ‘starter gun’ for lithium takeovers?
Eye on Lithium: Is Albemarle’s bid for LTR the ‘starter gun’ for lithium takeovers?

share Link copied to clipboard Liontown kicks Albermarle takeover offer to the cu...

Admin | Finance | 3 months ago

JioFiber Launches India’s Most Affordable Fixed Broadband Plan: ICICI Securities
JioFiber Launches India’s Most Affordable Fixed Broadband Plan: ICICI Securities

Reliance Jio has launched its most affordable fixed broadband plan starting at Rs 198/mont...

Admin | Finance | 3 months ago

India Strategy - Impact Of Adverse Weather Contained; Consumption Seen Steady: Nirmal Bang
India Strategy - Impact Of Adverse Weather Contained; Consumption Seen Steady: Nirmal Bang

We visited the Jodhpur region in Rajasthan and also interacted with agriculturalists and a...

Admin | Finance | 3 months ago

Addex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023
Addex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023

Geneva, Switzerland, March 28, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinica...

Admin | Finance | 3 months ago

Vivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development for the Treatment of Alzheimer's Disease
Vivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development for the Treatment of Alzheimer's Disease

Vivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development...

Admin | Finance | 3 months ago

Join Our Newsletter

join our newsletter to receive update from us